CANCER PREVENTION VS CANCER TREATMENT: THE RARE TUMOUR RISK SYNDROMES BATTLE

Información del proyecto

PREVENTABLE

Identificador del acuerdo de subvención: 101095483

DOI

10.3030/101095483

Fecha de la firma de la CE 2 Diciembre 2022

Fecha de inicio 1 Enero 2023

Fecha de finalización 30 Junio 2026

Financiado con arreglo a

• Health

Coste total

€ 4 686 000,00

Aportación de la UE

€ 4 642 249,75

Coordinado por

I3S - INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO
Portugal

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Resultado final

Other (4)

Cost-benefit model care pathways of RTRS and per RTRS 2
Identification of time windows for prophylactic intervention and estimation of disease-free survival for every condition-specific pathways of care and every RTRS
A set of condition-specific pathways of care for every RTRS and validated associated matrices of clinical procedures
Cost-benefit model care pathways of RTRS and per RTRS 1

Documents, reports (4)

Report on the survey findings for clinical teams and patients
SWOT Analysis of RTRS care pathways
Report on the focus groups findings for clinical teams, patients and their social care network
Report about RTRS policy and health systems obstacles and threats for pathways of care

Websites, patent fillings, videos etc. (4)

Dissemination & Exploitation Plan, including communication activities and RTRS-specific content 2

Dissemination & Exploitation Plan, including communication activities and RTRS-specificcontent 2

Dissemination & Exploitation Plan, including communication activities and RTRS-specific content 1

Dissemination & Exploitation Plan, including communication activities and RTRS-specificcontent 1

Project website
Dissemination & Exploitation Plan, including communication activities and RTRS-specific content 3

Dissemination & Exploitation Plan, including communication activities and RTRS-specificcontent 3

Publicaciones

Other (5)

Dissemination & Exploitation Plan, including communication activities and RTRS-specific content 2

Editor: CORDIS - EU research results

Project website

Editor: CORDIS - EU research results

PREVENTABLE: an European study on cost-effectiveness of prevention in rare tumour risk syndromes

Autores: Sara B. Pereira; Liliana Sousa; Ricardo Amorim; Luzia Garrido; Bárbara Peleteiro; Stefan Aretz; Judith Balmaña; Juan Brunet; Claude Houdayer; Svetlana Bajalica-Lagercrantz; Igor Lopes; Judite Gonçalves; Nuno Teixeira Marcos; Marta M. Marques; Céu Mateus;
Editor: Zenodo
DOI: 10.5281/ZENODO.14893719

Dissemination & Exploitation Plan, including communication activities and RTRS-specific content 1

Editor: CORDIS - EU research results

Cost-benefit model care pathways of RTRS and per RTRS 1

Editor: CORDIS - EU research results

Peer reviewed articles (3)

A protocol for karyotyping and genetic editing of induced pluripotent stem cells with homology-directed repair mediated CRISPR/Cas9

Autores: Silvana Lobo; Rita Barbosa-Matos; Sofia Dória; Ana Maria Pedro; Ana Brito; Daniel Ferreira; Carla Oliveira
Publicado en: Biology Methods and Protocols, 2025, ISSN 2396-8923
Editor: Oxford Academic
DOI: 10.5281/ZENODO.19560851

Behavioural analysis of referral and uptake of care pathways for rare tumour risk syndromes: A cross-cultural mixed-methods study protocol within the PREVENTABLE project

Autores: Ana Machado; Maiara Moreto; Isabel Fernandes; Ana Maria Rodrigues; Bárbara Peleteiro; Joan Brunet; Judith Balmaña; Claude Houdayer; Jean-Christophe Thery; Janneke H.M. Schuurs-Hoeijmakers; Stefan Aretz; Cathrine Bjorvatn; Liliana Sousa; Sara Pereira; Carla Oliveira; Marta M. Marques
Publicado en: Open Research Europe, 2025, ISSN 2732-5121
Editor: F1000 Research Ltd
DOI: 10.5281/ZENODO.19554868

Hereditary diffuse gastric cancer spectrum associated with germline <i>CTNNA1</i> loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls

Autores: Silvana Lobo, Alexandre Dias, Ana Maria Pedro, Marta Ferreira, André Pinto-Oliveira, Celina São José, Jennifer Herrera-Mullar, Nádia Pinto, Chrystelle Colas, Robert Hüneburg, Jacob Nattermann, Lise Boussemart, Liselotte P van Hest, Leticia Moreira, Carolyn Horton, Dana Farengo Clark, Sigrid Tinschert, Lisa Golmard, Isabel Spier, Adriá López-Fernández, Daniela Oliveira, Magali SVRCEK, Pierre Bourgoin, Florence Coulet, Hélène Delhomelle, Jeremy Davis, Birthe Zäncker, Conxi Lazaro, Joana Guerra, Maria L Almeida, Sergio Carrera, Ana Patiño, Paul Gundlach, Monika Laszkowska, Vivian E Strong, Manuel R Teixeira, Intan Schrader, Verena Steinke-Lange, Irene Gullo, Sérgio Sousa, Manuela Batista, Stefan Aretz, Judith Balmaña, Melyssa Aronson, Augusto Perazzolo Antoniazzi, Edenir I Palmero, Paul Mansfield, Lizet E van der Kolk, Annemieke Cats, Jolanda M van Dieren, Sergi Castellví-Bel, Bryson Katona, Rachid Karam, Paulo S Pereira, Patrick R Benusiglio, Carla Oliveira
Publicado en: Gut, 2025, ISSN 0017-5749
Editor: BMJ
DOI: 10.1136/GUTJNL-2024-334601